NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/26/2024
Back to search
Official data from USPTO
COST PLUS DRUGS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
COST PLUS DRUGS
ST13
US500000097307445Class
5
Filing
97307445
Registration
7582440
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
11/26/2024
Trademark type
Word
Nice classes
5
Filing date
03/11/2022
Registration date
11/26/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/26/2024
Last transaction
11/26/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
2024-05-00
First use in commerce
2024-05-00
Drawing code
4
Owner type
03
Owner location
Littleton, CO, US
Examiner
CORDANI, CAITLIN A
Law office
L90
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Mark Cuban Cost Plus Drug Company, PBC
Representatives
Diana Rutowski & Seth Reagan ORRICK, HERRINGTON & SUTCLIFFE LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
House mark for a full line of pharmaceutical preparations
Publications
History of USPTO decisions and trademark events.
32 publications found
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
11/26/2024
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
10/30/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
10/29/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/29/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
10/29/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/29/2024
IUAA
USE AMENDMENT ACCEPTED
10/22/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/01/2024
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
09/20/2024
ALIE
ASSIGNED TO LIE
09/20/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/13/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/13/2024
IUAF
USE AMENDMENT FILED
05/09/2024
EAAU
TEAS AMENDMENT OF USE RECEIVED
05/09/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
02/12/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
02/12/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/15/2023
GNFR
FINAL REFUSAL E-MAILED
11/15/2023
CNFR
FINAL REFUSAL WRITTEN
11/15/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/28/2023
GNSL
LETTER OF SUSPENSION E-MAILED
04/28/2023
CNSL
SUSPENSION LETTER WRITTEN
04/28/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/10/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/28/2022
GNRT
NON-FINAL ACTION E-MAILED
12/28/2022
CNRT
NON-FINAL ACTION WRITTEN
12/28/2022
DOCK
ASSIGNED TO EXAMINER
12/22/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/16/2022
NWAP
NEW APPLICATION ENTERED
03/15/2022
Continuous trademark protection
Get notified about every new filing that threatens COST PLUS DRUGS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.